Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

667 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A phase II randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond 6 cycles in patients with glioblastoma (GEINO 14-01).
Balana C, Vaz MA, Manuel Sepúlveda J, Mesia C, Del Barco S, Pineda E, Muñoz-Langa J, Estival A, de Las Peñas R, Fuster J, Gironés R, Navarro LM, Gil-Gil M, Alonso M, Herrero A, Peralta S, Olier C, Perez-Segura P, Covela M, Martinez-García M, Berrocal A, Gallego O, Luque R, Perez-Martín FJ, Esteve A, Munne N, Domenech M, Villa S, Sanz C, Carrato C. Balana C, et al. Among authors: villa s. Neuro Oncol. 2020 Dec 18;22(12):1851-1861. doi: 10.1093/neuonc/noaa107. Neuro Oncol. 2020. PMID: 32328662 Free PMC article. Clinical Trial.
Neoadjuvant cisplatin plus temozolomide versus standard treatment in patients with unresectable glioblastoma or anaplastic astrocytoma: a differential effect of MGMT methylation.
Capdevila L, Cros S, Ramirez JL, Sanz C, Carrato C, Romeo M, Etxaniz O, Hostalot C, Massuet A, Cuadra JL, Villà S, Balañà C. Capdevila L, et al. Among authors: villa s. J Neurooncol. 2014 Mar;117(1):77-84. doi: 10.1007/s11060-013-1352-7. Epub 2014 Jan 7. J Neurooncol. 2014. PMID: 24395350 Clinical Trial.
Bevacizumab and temozolomide versus temozolomide alone as neoadjuvant treatment in unresected glioblastoma: the GENOM 009 randomized phase II trial.
Balana C, De Las Penas R, Sepúlveda JM, Gil-Gil MJ, Luque R, Gallego O, Carrato C, Sanz C, Reynes G, Herrero A, Ramirez JL, Pérez-Segura P, Berrocal A, Vieitez JM, Garcia A, Vazquez-Estevez S, Peralta S, Fernandez I, Henriquez I, Martinez-Garcia M, De la Cruz JJ, Capellades J, Giner P, Villà S. Balana C, et al. Among authors: villa s. J Neurooncol. 2016 May;127(3):569-79. doi: 10.1007/s11060-016-2065-5. Epub 2016 Feb 3. J Neurooncol. 2016. PMID: 26847813 Clinical Trial.
Pseudoprogression as an adverse event of glioblastoma therapy.
Balaña C, Capellades J, Pineda E, Estival A, Puig J, Domenech S, Verger E, Pujol T, Martinez-García M, Oleaga L, Velarde J, Mesia C, Fuentes R, Marruecos J, Del Barco S, Villà S, Carrato C, Gallego O, Gil-Gil M, Craven-Bartle J, Alameda F; GLIOCAT Group. Balaña C, et al. Among authors: villa s. Cancer Med. 2017 Dec;6(12):2858-2866. doi: 10.1002/cam4.1242. Epub 2017 Nov 3. Cancer Med. 2017. PMID: 29105360 Free PMC article.
RNA sequencing and Immunohistochemistry Reveal ZFN7 as a Stronger Marker of Survival than Molecular Subtypes in G-CIMP-negative Glioblastoma.
Esteve-Codina A, Alameda F, Carrato C, Pineda E, Arpí O, Martinez-García M, Mallo M, Gut M, Dabad M, Tortosa A, Del Barco S, Capellades J, Puig J, Gallego O, Pujol T, Oleaga L, Gil-Gil M, de Quintana-Schmidt C, Valduvieco I, Martinez-Cardús A, Bellosillo B, Muñoz-Marmol AM, Esteve A, Domenech M, Camins A, Craven-Bartle J, Villa S, Marruecos J, Domenech S, de la Iglesia N, Balana C. Esteve-Codina A, et al. Among authors: villa s. Clin Cancer Res. 2021 Jan 15;27(2):645-655. doi: 10.1158/1078-0432.CCR-20-2141. Epub 2020 Oct 26. Clin Cancer Res. 2021. PMID: 33106291
Evolution of care for patients with relapsed glioblastoma.
Balañá C, Villá S, Teixidor P. Balañá C, et al. Among authors: villa s. Expert Rev Anticancer Ther. 2011 Nov;11(11):1719-29. doi: 10.1586/era.11.152. Expert Rev Anticancer Ther. 2011. PMID: 22050021 Review.
Delay in starting radiotherapy due to neoadjuvant therapy does not worsen survival in unresected glioblastoma patients.
Balaña C, Estival A, Teruel I, Hardy-Werbin M, Sepulveda J, Pineda E, Martinez-García M, Gallego O, Luque R, Gil-Gil M, Mesia C, Del Barco S, Herrero A, Berrocal A, Perez-Segura P, De Las Penas R, Marruecos J, Fuentes R, Reynes G, Velarde JM, Cardona A, Verger E, Panciroli C, Villà S. Balaña C, et al. Among authors: villa s. Clin Transl Oncol. 2018 Dec;20(12):1529-1537. doi: 10.1007/s12094-018-1883-7. Epub 2018 May 8. Clin Transl Oncol. 2018. PMID: 29737461
Results of a multicenter survey showing interindividual variability among neurosurgeons when deciding on the radicality of surgical resection in glioblastoma highlight the need for more objective guidelines.
Capellades J, Teixidor P, Villalba G, Hostalot C, Plans G, Armengol R, Medrano S, Estival A, Luque R, Gonzalez S, Gil-Gil M, Villa S, Sepulveda J, García-Mosquera JJ, Balana C. Capellades J, et al. Among authors: villa s. Clin Transl Oncol. 2017 Jun;19(6):727-734. doi: 10.1007/s12094-016-1598-6. Epub 2016 Dec 22. Clin Transl Oncol. 2017. PMID: 28005261
667 results